Compare BBGI & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBGI | DARE |
|---|---|---|
| Founded | 1961 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 16.6M |
| IPO Year | 1999 | 2014 |
| Metric | BBGI | DARE |
|---|---|---|
| Price | $8.80 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 29.3K | ★ 187.9K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 48.01 | N/A |
| Revenue | ★ $232,179,463.00 | $2,807,885.00 |
| Revenue This Year | N/A | $163.80 |
| Revenue Next Year | $0.47 | $226.14 |
| P/E Ratio | $0.18 | ★ N/A |
| Revenue Growth | ★ 69.89 | N/A |
| 52 Week Low | $3.14 | $0.69 |
| 52 Week High | $29.30 | $3.78 |
| Indicator | BBGI | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 22.56 | 36.65 |
| Support Level | $3.50 | $0.70 |
| Resistance Level | $24.70 | $0.88 |
| Average True Range (ATR) | 1.29 | 0.05 |
| MACD | -0.14 | -0.00 |
| Stochastic Oscillator | 12.98 | 2.40 |
Beasley Broadcast Group Inc is a multi-platform media company whose primary business is operating radio stations throughout the United States. The company offers local and national advertisers integrated marketing solutions across audio, digital and event platforms. It owns and operates stations in the following markets: Atlanta, GA; Augusta, GA; Boston, MA; Charlotte, NC; Detroit, MI; Fayetteville, NC; Fort Myers-Naples, FL; Las Vegas, NV; Middlesex, NJ; Monmouth, NJ; Morristown, NJ; Philadelphia, PA; Tampa-Saint Petersburg, FL; and Wilmington, DE. The company operates in two segments: Audio, which generates the maximum revenue, and Digital.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.